Wode, Kathrin http://orcid.org/0000-0001-6449-6349
Hök Nordberg, Johanna
Kienle, Gunver S.
Elander, Nils O.
Bernhardson, Britt-Marie
Sunde, Berit
Sharp, Lena
Henriksson, Roger
Fransson, Per
Funding for this research was provided by:
Onkologklinikens Gåvofond; Karolinska University Hospital (K0777-2011)
The Cancer Research Funds of Radiumhemmet (134182)
Signe ja Ane Gyllenbergin Säätiö (May 2018)
Ekhaga foundation (2016-84)
Dagmar Ferbs Memorial fund (June 2014)
Cancer Research Foundation in Northern Sweden (AMP16-816)
The Sjoberg Foundation (Date 2 Jan 2019)
Signe ja Ane Gyllenbergin Säätiö (May 2014, May 2020)
Article History
Received: 14 April 2020
Accepted: 4 July 2020
First Online: 11 September 2020
Ethics approval and consent to participate {24}
: The study protocol has been written, and the trial is being performed in accordance with the general ethical principles outlined in the Declaration of Helsinki [CitationRef removed] and in accordance with the current GCP Guidelines from The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [CitationRef removed]. Ethical approval was obtained on 2nd March 2016 from the Regional Ethical Review Board in Stockholm (Dnr. 2016/122-31/2). Approval from the Swedish Medical Products Agency was obtained on 12th April 2016 (EudraCT number 2014-004552-64, Dnr. 5.1-2015-101435). Important protocol modifications are communicated according to national requirements to the Swedish Ethic Review Authority, the Swedish Medical Products Agency and participating sites as appropriate.Written informed consent will be obtained from all study participants prior to any trial-related procedures.
: Informed consent forms are available from the corresponding author on request.
: The authors declare that they have no competing interests.